文献速递前列腺癌

循环髓源性抑制细胞与前列腺癌患者生存:系统综述与Meta分析

Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-11-21

该系统综述与Meta分析从Pubmed检索的133项研究中纳入5项合格研究(共236例前列腺癌患者),比较高循环MDSC水平与低水平患者的总生存期(OS)。高循环MDSC水平与更差OS相关(HR=2.19;95%CI=1.51-3.17),异质性不显著(I²=0%;p=0.64),发表偏倚不显著(Egger检验,p=0.09)。结论认为高循环MDSC水平诱导更差OS,支持在前列腺癌患者中检测和靶向MDSC的重要性。

要点

  • 高循环MDSC水平与前列腺癌患者更差的总生存期相关(HR=2.19;95%CI=1.51-3.17)。
  • 异质性不显著(I²=0%;p=0.64),发表偏倚不显著(Egger检验,p=0.09)。
  • 共纳入5项研究、236例前列腺癌患者,支持检测和靶向MDSC的重要性。

核心结论

  • 高循环MDSC水平的前列腺癌患者总生存期较低水平患者更差(HR=2.19;95%CI=1.51-3.17)。
  • 该发现支持在前列腺癌患者中检测和靶向MDSC的重要性。

研究设计与样本

  • 系统综述与Meta分析,从Pubmed检索的133项研究中纳入5项合格研究,共236例前列腺癌患者。
  • 比较前列腺癌患者高循环MDSC水平与低水平的生存差异,提取或计算总生存期(OS)的HR及相对95%CI。
  • 计算合并HR及相对95%CI,并评估发表偏倚。

主要发现

  • 高循环MDSC水平与更差OS相关(HR=2.19;95%CI=1.51-3.17)。
  • 异质性不显著(I²=0%;p=0.64)。
  • 发表偏倚不显著(Egger检验,p=0.09)。

关键数值与推荐

  • 高循环MDSC水平患者OS的合并HR=2.19(95%CI=1.51-3.17)。
  • 异质性I²=0%(p=0.64)。
  • 发表偏倚Egger检验p=0.09。

临床怎么用

  • 原文结论支持在前列腺癌患者中检测和靶向MDSC的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunotherapy has not achieved improvement of survival in prostate cancer patients. Myeloid-derived suppressor cells (MDSCs) in tumor microenvironment can hamper its efficacy. Some preclinical studies explored the role of MDSCs in prostate cancer development. We aimed to verify the availability of studies exploring the prognostic effect of circulating MDSCs in prostate cancer patients. METHODS: We systematically selected studies for a meta-analysis, which compares survival between prostate cancer patients with high vs low circulating MDSC levels. We extracted or calculated hazard ratios (HRs) and relative 95% confidence intervals (CIs) in terms of overall survival (OS) from selected studies. We calculated the pooled HR and relative 95% CIs and estimated publication bias. RESULTS: Among 133 studies retrieved from search on Pubmed, 5 eligible studies (236 prostate cancer patients) met inclusion criteria. High circulating MDSC levels are associated with a worse OS (HR = 2.19; 95%CI = 1.51-3.17). Heterogeneity was not significant (I2 = 0%; p = 0.64). Publication bias was also not significant (Egger's test, p = 0.09). CONCLUSIONS: High levels of circulating MDSCs induce a worse OS in prostate cancer patients than in those with low levels. This finding supports the importance of MDSC detection and targeting also in prostate cancer patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Bronte G, Conteduca V, Landriscina M, et al. Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2022. PMID: 36411316. doi:10.1038/s41391-022-00615-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。